/** Alembic’s Q1 FY27: US momentum, steady India, and a new branded bet

*/

Alembic’s Q1 FY27: US momentum, steady India, and a new branded bet

Alembic Pharmaceuticals began FY27 with a strong Q1 performance, helped by broad-based growth across India, the US, ex-US markets, and APIs. Consolidated revenue rose to INR 21.50 billion, up 26% year-on-year. Profitability improved even while the company continued to fund future growth platforms. EBITDA after R&D stood at 16% of revenue, and reported profit after tax was INR 1.73 billion, up 12% year-on-year.

The headline number came from the US formulation business, where revenues rose 49% year-on-year to INR 7.78 billion. Management attributed this to volume-driven growth and new launches in an environment that still faces pricing pressure. Ex-US formulations also delivered 17% growth, while APIs grew 33% on the back of a strong order book. India branded business was steadier at 7% growth, with management highlighting that animal health outperformed and that improvements in human health execution may take a couple of quarters.

Segment performance: US leads, APIs rebound, India steadies

In Q1 FY27, the US became the largest single contributor to quarterly revenue at 36% of the mix, followed by India at 30%, ex-US at 18%, and APIs at 16%. The US growth was supported by seven product launches during the quarter, four ANDA filings, and ten approvals. As of June 30, 2026, Alembic disclosed a cumulative base of 279 ANDA filings, 244 approvals (including tentative approvals), and 185 products launched in the US.

India’s branded business delivered INR 6.42 billion for the quarter. The presentation pointed to a large field force and a wide brand base, but management commentary indicated the company has been underperforming market growth in parts of human health. A new Sales and Marketing Head for Human Health has been appointed, and management said improvements would likely become visible over the next one to two quarters. Within India, the animal health business was a bright spot, with Q1 revenue of INR 1,410 million and 24% year-on-year growth.

Ex-US revenues reached INR 3.83 billion, aided by partnerships across Europe, Canada, Australia, Brazil, Chile, and South Africa. The company also highlighted a Canada joint venture and new subsidiaries in Thailand, the Philippines, and Germany as part of its international expansion effort.

API revenues rose to INR 3.46 billion, up 33% year-on-year. The presentation disclosed three US DMF filings in Q1 FY27 and a cumulative 152 DMF filings. Management maintained that cost efficiency remains a priority to stay competitive.

Margins and investments: operating leverage meets planned spend

Alembic’s Q1 commentary reflects a familiar trade-off: operating leverage from higher volumes versus planned spending in R&D and a new US branded platform. The company reported R&D at about 9% of revenue in Q1, and management tied the increase to peptide development activities, exhibit batches, and higher regulatory filings.

A key theme in the call was the ramp-up of the US branded specialty business. Management described the first three months as a soft launch for Pivya with encouraging response and mentioned adding products such as Nuvessa to strengthen a women’s health franchise. The company stated that this initiative requires no manufacturing or facility investment because products are sourced via a CMO. Instead, the costs are largely field force and marketing expenses.

Because of this, management acknowledged near-term margin pressure. The CFO reiterated a full-year margin dilution guidance of about 150 basis points due to US branded spending. They also indicated that Q1’s impact was higher, with gradual moderation expected as sales build. Management’s stated intent is to see the margin drag reduce quarter-on-quarter, trend toward breakeven by the end of FY27, and deliver positive contribution from the next financial year.

Gross margins were discussed as well. Management cited solvent price increases linked to Middle East disruptions, product mix, and under-absorption due to a preventive maintenance shutdown in an ophthalmic facility. The shutdown, according to the CFO, also helped expand capacity without incremental capex.

Debt and finance costs drew attention in the Q&A. The CFO stated gross debt was around INR 1,600 crore as of the quarter, higher than March due to receivables rising with sales. Management expects receivables to unwind over the next quarters, bringing debt back at least to March levels and reducing interest cost.

What management changed in FY27 guidance

Management used Q1 performance to raise confidence levels for the year. At the start of FY27, Alembic indicated US generics could grow in the low to mid-teens. After Q1, management revised that expectation upward to mid to high teens for FY27, subject to normal market conditions and continued execution.

At the consolidated level, management raised the company’s overall growth outlook for FY27 from low double-digit to closer to mid-teen. Importantly, management emphasized that the improved outlook is not driven by reduced investment. The company intends to keep investing in R&D, the US branded platform, and manufacturing improvements, while maintaining discipline on capital allocation.

For India, management’s tone was realistic rather than celebratory. The company reiterated focus areas such as building a chronic portfolio, improving prescription quality, and deepening engagement with specialists. The new leadership in human health sales and marketing is expected to help execution, but management said the impact may take a couple of quarters.

In ex-US markets, management reiterated confidence in sustaining growth, while acknowledging quarterly variability because much of the business is B2B in nature.

Takeaways from Q1 FY27

Alembic’s Q1 FY27 message was consistent across the presentation and concall: the core growth engine is running better, especially in the US generics business, and management is using this phase to invest into the next platform through US branded specialty and R&D. The company’s revised FY27 outlook suggests stronger visibility in the US pipeline and launch calendar, while the margin trajectory will depend on how quickly the branded US business scales.

For investors, the quarter sets up three practical markers to watch through FY27: whether US launches continue at the guided pace, whether India human health execution improves after leadership changes, and whether the US branded business begins to reduce its margin drag toward management’s stated breakeven trend by year-end.